The sample’s data collected for a 4-year period (2018–2021) comprise information on clinical diagnosis, demographics, histopathology diagnosis, and molecular screening results for the 3 CRC actionable genes (BRAF, KRAS, NRAS). This evidence concerns the gene NRAS and colorectal carcinoma.